Standard-of-Care HRRm Testing Underutilized in Patients With mCRPC
January 25th 2024Despite germline and somatic testing being the standard of care for patients with metastatic castration-resistant prostate cancer, rates of its real-world use shows that it may be underutilized, which may negatively impact therapeutic offerings.